Endocrine Abstracts

Introduction: Diabetes mellitus is not just a disease as it is already known, the matter is more complicated, and it is considered as an assembly of metabolic defects with end result of hyperglycemia. verapamil can decrease the expression of thioredoxin-interacting protein (TXNIP), which is recognized as an important factor in pancreatic beta cells. verapamil could enhance beta cell mass and function.

Materials and methods: 160 type 2 diabetes mellitus and hypertensive patients into 2 parallel groups. Each group had 80 patients, 50 males and 30 females. All patients were monitored in a private clinic. All the patients Lied between 30-60 years old. All patients are on maximum doses of glimepiride, sitagliptin, metformin and empagliflozin but are uncontrolled on this combination with hba1c more than 8. The first group received verapamil 240 mg as substitute or added to the present hypertension therapy for 6 months. The second group was still on hypertensive therapy but received lantus 20 units added to the oral therapy. We measured hba1c and c-peptide levels in the 2 groups at the start of the trial and after 6 months of the trial.

Results: The results show a statistically significant difference in hba1c in group 1 patients before and after 6 months of treatment with verapamil With P value less than 0.0001. The results show statistically significant difference in hba1c in group 2 patients with P value less than 0.0001. The results show significant differences in c-peptide levels in group 1 patients before and after 6 months of treatment of verapamil. The results show non-significant differences in c-peptide levels in group 2 patients before and after 6 months treatment of basal insulin with b value 0.9822. The results show significant difference in hba1c after 6 months of treatment of verapamil vs. basal insulin with b value less than 0.0001. Results also show that verapamil can increase c-peptide levels after 6 months of treatment.

Conclusion: Verapamil could be used as a type 2 diabetes saviour by increasing beta cell mass and function.

Key words: type 2 diabetes mellitus, verapamil, (TXNIP), beta cells